{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T04:50:53Z","timestamp":1771735853895,"version":"3.50.1"},"reference-count":164,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100004054","name":"Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi Arabia","doi-asserted-by":"publisher","award":["IFFPP-79-22"],"award-info":[{"award-number":["IFFPP-79-22"]}],"id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAR"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Behavioral and psychotic manifestations, including aggression, delusions, and hallucinations,\nare frequent comorbidities in patients with debilitating nervous illnesses such as Alzheimer\u2019s\ndisease (AD), Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson\u2019s disease. ADrelated\npsychosis may be linked to a poor disease prognosis, highlighting that early detection and\nmanagement are mandatory. The manifestations are variable and may be very heterogeneous, imposing\na real diagnostic issue. Some assessment tools such as BEHAVE-AD, CERAD-BRSD, and the\nPsycho-Sensory Hallucinations Scale have been designed to facilitate the diagnosis. The mechanisms\nbehind neurodegeneration-related psychosis are complex and are not fully understood, imposing a\nburden on researchers to find appropriate management modalities. Familial history and some genetic\ndisturbances may have a determinant role in these delusions and hallucinations in cases with AD.\nThe loss of neuronal cells, atrophy in some regions of the central nervous, and synaptic dysfunction\nmay also contribute to these comorbidities. Furthermore, inflammatory disturbances triggered by\npro-inflammatory agents such as interleukins and tumor necrosis factors are stratified among the potential\nrisk factors for the onset of numerous psychotic symptoms in Alzheimer\u2019s patients. Little is\nknown about the possible management tools; therefore, it is urgent to conduct well-designed trials to\ninvestigate pharmacological and non-pharmacological interventions that can improve the care process\nof these patients. This review summarizes the current findings regarding the AD-related psychosis\nsymptoms, pathological features, assessment, and management.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567205019666220418151914","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T07:31:58Z","timestamp":1650439918000},"page":"285-301","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Alzheimer\u2019s Disease-Related Psychosis: An Overview of Clinical Manifestations,\nPathogenesis, and Current Treatment"],"prefix":"10.2174","volume":"19","author":[{"given":"Amira Y.","family":"Benmelouka","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Algiers, Algiers, Algeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yassamine","family":"Ouerdane","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Saad Dahlab University, Blida, Algeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oumaima","family":"Outani","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy of Rabat, Mohammed 5 University, Rabat, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusra T.","family":"Alnasser","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy,\nDamascus University, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badrah S.","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Department of Physiology, Neuroscience Unit, Faculty of Medicine, King Abdulaziz\nUniversity, Jeddah, Saudi Arabia"},{"name":"Pre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz\nUniversity, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Perveen","sequence":"additional","affiliation":[{"name":"Glocal School of Life Sciences, Glocal University, Mirzapur Pole, Saharanpur,\nUttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam Md.","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Pre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz\nUniversity, Jeddah, Saudi Arabia"},{"name":"Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences,\nKing Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5284-2929","authenticated-orcid":true,"given":"Mahmoud Ahmed","family":"Ebada","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Zagazig University, Zagazig, Al-Sharkia,\nEgypt"},{"name":"Resident Physician, Egyptian Fellowship of Neurology, Nasr City Hospital For Health Insurance, Cairo Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4572471","volume":"2021","author":"Ashraf G.M.","year":"2021","unstructured":"Ashraf G.M.; Ebada M.A.; Suhail M.; Dissecting sex-related cognition between alzheimer\u2019s disease and diabetes: From molecular mechanisms to potential therapeutic strategies. Oxid Med Cell Longev 2021,2021","journal-title":"Oxid Med Cell Longev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/gim.2015.117","volume":"18","author":"Van Cauwenberghe C.","year":"2016","unstructured":"Van Cauwenberghe C.; Van Broeckhoven C.; Sleegers K.; The genetic landscape of Alzheimer disease: Clinical implications and perspectives. Genet Med 2016,18(5),421-430","journal-title":"Genet Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"McKhann G.","year":"1984","unstructured":"McKhann G.; Drachman D.; Folstein M.; Katzman R.; Price D.; Stadlan E.M.; Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 1984,34(7),939-944","journal-title":"Neurology"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/j.1532-5415.1995.tb07401.x","volume":"43","author":"Jost B.C.","year":"1995","unstructured":"Jost B.C.; Grossberg G.T.; The natural history of Alzheimer\u2019s disease: A brain bank study. J Am Geriatr Soc 1995,43(11),1248-1255","journal-title":"J Am Geriatr Soc"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","volume":"14","year":"2018","unstructured":"2018 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2018,14(3),367-429","journal-title":"Alzheimers Dement"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"Sperling R.A.","year":"2011","unstructured":"Sperling R.A.; Aisen P.S.; Beckett L.A.; Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 2011,7(3),280-292","journal-title":"Alzheimers Dement"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"Dubois B.","year":"2014","unstructured":"Dubois B.; Feldman H.H.; Jacova C.; Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria. Lancet Neurol 2014,13(6),614-629","journal-title":"Lancet Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013950","volume":"5","author":"Jones L.","year":"2010","unstructured":"Jones L.; Holmans P.A.; Hamshere M.L.; Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer\u2019s disease. PLoS One 2010,5(11)","journal-title":"PLoS One"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ng.803","volume":"43","author":"Hollingworth P.","year":"2011","unstructured":"Hollingworth P.; Harold D.; Sims R.; Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer\u2019s disease. Nat Genet 2011,43(5),429-435","journal-title":"Nat Genet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","volume":"13","author":"Gratuze M.","year":"2018","unstructured":"Gratuze M.; Leyns C.E.G.; Holtzman D.M.; New insights into the role of TREM2 in Alzheimer\u2019s disease. Mol Neurodegener 2018,13(1),66","journal-title":"Mol Neurodegener"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12974-019-1399-2","volume":"16","author":"Nordengen K.","year":"2019","unstructured":"Nordengen K.; Kirsebom B-E.; Henjum K.; Glial activation and inflammation along the Alzheimer\u2019s disease continuum. J Neuroinflammation 2019,16(1),46","journal-title":"J Neuroinflammation"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/brain\/aww349","volume":"140","author":"Fan Z.","year":"2017","unstructured":"Fan Z.; Brooks D.J.; Okello A.; Edison P.; An early and late peak in microglial activation in Alzheimer\u2019s disease trajectory. Brain 2017,140(3),792-803","journal-title":"Brain"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.3233\/JAD-179929","volume":"64","author":"Edison P.","year":"2018","unstructured":"Edison P.; Brooks D.J.; Role of neuroinflammation in the trajectory of alzheimer\u2019s disease and in vivo quantification using PET. J Alzheimers Dis 2018,64(s1),S339-S351","journal-title":"J Alzheimers Dis"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/brain\/awx120","volume":"140","author":"Parbo P.","year":"2017","unstructured":"Parbo P.; Ismail R.; Hansen K.V.; Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer\u2019s disease. Brain 2017,140(7),2002-2011","journal-title":"Brain"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s12035-014-8657-1","volume":"50","author":"Brosseron F.","year":"2014","unstructured":"Brosseron F.; Krauthausen M.; Kummer M.; Heneka M.T.; Body fluid cytokine levels in mild cognitive impairment and Alzheimer\u2019s disease: A comparative overview. Mol Neurobiol 2014,50(2),534-544","journal-title":"Mol Neurobiol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"Heneka M.T.","year":"2015","unstructured":"Heneka M.T.; Carson M.J.; El Khoury J.; Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 2015,14(4),388-405","journal-title":"Lancet Neurol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2174\/1567205014666170829100100","volume":"15","author":"Businaro R.","year":"2018","unstructured":"Businaro R.; Corsi M.; Asprino R.; Modulation of inflammation as a way of delaying Alzheimer\u2019s disease progression: The diet\u2019s role. Curr Alzheimer Res 2018,15(4),363-380","journal-title":"Curr Alzheimer Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-981-13-9636-6_8","author":"Benmelouka A.","year":"2019","unstructured":"Benmelouka A.; Sherif A.M.; Ebada M.A.;  A review of the relationship between gut microbiota and memory Biological singapore: Diagnostic and therapeutic advances in Alzheimer\u2019s disease 2019,151-165","journal-title":"A review of the relationship between gut microbiota and memory Biological singapore: Diagnostic and therapeutic advances in Alzheimer\u2019s disease"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8501693","volume":"2016","author":"Folch J.","year":"2016","unstructured":"Folch J.; Petrov D.; Ettcheto M.; Current research therapeutic strategies for alzheimer\u2019s disease treatment. Neural Plast 2016,2016","journal-title":"Neural Plast"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1177\/1533317515622283","volume":"31","author":"Shi X.","year":"2016","unstructured":"Shi X.; Lin X.; Hu R.; Sun N.; Hao J.; Gao C.; Toxicological differences between NMDA receptor antagonists and cholinesterase inhibitors. Am J Alzheimers Dis Other Demen 2016,31(5),405-412","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fncel.2015.00186","volume":"9","author":"Chen M.","year":"2015","unstructured":"Chen M.; The maze of APP processing in Alzheimer\u2019s disease: where did we go wrong in reasoning? Front Cell Neurosci 2015,9,186","journal-title":"Front Cell Neurosci"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2589276","volume":"2016","author":"Mendiola-Precoma J.","year":"2016","unstructured":"Mendiola-Precoma J.; Berumen L.C.; Padilla K.; Garcia-Alcocer G.; Therapies for prevention and treatment of Alzheimer\u2019s disease. BioMed Res Int 2016,2016","journal-title":"BioMed Res Int"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3233\/JAD-170786","volume":"63","author":"Wang J-H.","year":"2018","unstructured":"Wang J-H.; Wu Y-J.; Tee B.L.; Lo R.Y.; Medical comorbidity in alzheimer\u2019s disease: A nested case-control study. J Alzheimers Dis 2018,63(2),773-781","journal-title":"J Alzheimers Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"Salloway S.","year":"2014","unstructured":"Salloway S.; Sperling R.; Fox N.C.; Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 2014,370(4),322-333","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/qjmed\/hcr118","volume":"104","author":"Duthie A.","year":"2011","unstructured":"Duthie A.; Chew D.; Soiza R.L.; Non-psychiatric comorbidity associated with Alzheimer\u2019s disease. QJM 2011,104(11),913-920","journal-title":"QJM"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1590\/0001-3765201520140716","volume":"87","author":"Garcez M.L.","year":"2015","unstructured":"Garcez M.L.; Falchetti A.C.B.; Mina F.; Budni J.; Alzheimer\u2019s disease associated with psychiatric comorbidities. An Acad Bras Cienc 2015,87(2)(Suppl.),1461-1473","journal-title":"An Acad Bras Cienc"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1176\/ajp.149.2.184","volume":"149","author":"Jeste D.V.","year":"1992","unstructured":"Jeste D.V.; Wragg R.E.; Salmon D.P.; Harris M.J.; Thal L.J.; Cognitive deficits of patients with Alzheimer\u2019s disease with and without delusions. Am J Psychiatry 1992,149(2),184-189","journal-title":"Am J Psychiatry"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1017\/S1355617700677081","volume":"6","author":"Paulsen J.S.","year":"2000","unstructured":"Paulsen J.S.; Ready R.E.; Stout J.C.; Neurobehaviors and psychotic symptoms in Alzheimer\u2019s disease. J Int Neuropsychol Soc 2000,6(7),815-820","journal-title":"J Int Neuropsychol Soc"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jagp.2013.01.051","volume":"21","author":"Vilalta-Franch J.","year":"2013","unstructured":"Vilalta-Franch J.; L\u00f3pez-Pousa S.; Calv\u00f3-Perxas L.; Garre-Olmo J.; Psychosis of Alzheimer disease: Prevalence, incidence, persistence, risk factors, and mortality. Am J Geriatr Psychiatry 2013,21(11),1135-1143","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1176\/appi.ajp.162.11.2022","volume":"162","author":"Ropacki S.A.","year":"2005","unstructured":"Ropacki S.A.; Jeste D.V.; Epidemiology of and risk factors for psychosis of Alzheimer\u2019s disease: A review of 55 studies published from 1990 to 2003. Am J Psychiatry 2005,162(11),2022-2030","journal-title":"Am J Psychiatry"},{"key":"ref=31","first-page":"647","volume":"73","year":"2006","unstructured":"G OJ, S B. Behavior disorders of dementia. Am Fam Physician R AV2006,73(4),647-652","journal-title":"Am Fam Physician"},{"key":"ref=32","first-page":"2335","volume":"67","author":"Motsinger C.D.","year":"2003","unstructured":"Motsinger C.D.; Perron G.A.; Lacy T.J.; Use of atypical antipsychotic drugs in patients with dementia. Am Fam Physician 2003,67(11),2335-2340","journal-title":"Am Fam Physician"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/jama.1997.03550160083043","volume":"278","author":"Small G.W.","year":"1997","unstructured":"Small G.W.; Rabins P.V.; Barry P.P.; Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer\u2019s Association, and the American Geriatrics Society. JAMA 1997,278(16),1363-1371","journal-title":"JAMA"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/gps.930080906","volume":"8","author":"Haupt M.","year":"1993","unstructured":"Haupt M.; Kurz A.; Predictors of nursing home placement in patients with alzheimer\u2019s disease. Int J Geriatr Psychiatry 1993,8(9),741-746","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ajp.2017.01.002","volume":"26","author":"Sinha P.","year":"2017","unstructured":"Sinha P.; Desai N.G.; Prakash O.; Kushwaha S.; Tripathi C.B.; Caregiver burden in Alzheimer-type dementia and psychosis: A comparative study from India. Asian J Psychiatr 2017,26,86-91","journal-title":"Asian J Psychiatr"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1176\/ajp.152.9.1349","volume":"152","author":"Tariot P.N.","year":"1995","unstructured":"Tariot P.N.; Mack J.L.; Patterson M.B.; The behavior rating scale for dementia of the consortium to establish a registry for alzheimer\u2019s disease. the behavioral pathology committee of the consortium to establish a registry for alzheimer\u2019s disease. Am J Psychiatry 1995,152(9),1349-1357","journal-title":"Am J Psychiatry"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/00019442-200307000-00003","volume":"11","author":"Cook S.E.","year":"2003","unstructured":"Cook S.E.; Miyahara S.; Bacanu S-A.; Psychotic symptoms in Alzheimer disease: Evidence for subtypes. Am J Geriatr Psychiatry 2003,11(4),406-413","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=38","first-page":"11","author":"Review L.","year":"2004","unstructured":"Review L.; Delusions in Alzheimer\u2019s Disease : A Literature Review. 2004,11-15"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/00019442-200511000-00009","volume":"13","author":"Wilson R.S.","year":"2005","unstructured":"Wilson R.S.; Krueger K.R.; Kamenetsky J.M.; Hallucinations and mortality in Alzheimer disease. Am J Geriatr Psychiatry 2005,13(11),984-990","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1212\/WNL.44.3_Part_1.523","volume":"44","author":"Lerner A.J.","year":"1994","unstructured":"Lerner A.J.; Koss E.; Patterson M.B.; Concomitants of visual hallucinations in Alzheimer\u2019s disease. Neurology 1994,44(3 Pt 1),523-527","journal-title":"Neurology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1176\/ajp.153.2.243","volume":"153","author":"Aarsland D.","year":"1996","unstructured":"Aarsland D.; Cummings J.L.; Yenner G.; Miller B.; Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer\u2019s disease. Am J Psychiatry 1996,153(2),243-247","journal-title":"Am J Psychiatry"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1992.tb01861.x","author":"Francis J.","year":"1992","unstructured":"Francis J.; Delusions, delirium, and cognitive impairment: The challenge of clinical heterogeneity. 1992"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"5s","DOI":"10.1016\/S0924-9338(00)00524-1","volume":"16","author":"Monteiro I.M.","year":"2001","unstructured":"Monteiro I.M.; Boksay I.; Auer S.R.; Torossian C.; Ferris S.H.; Reisberg B.; Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer\u2019s Disease Rating Scale: The BEHAVE-AD-FW: Methodology and reliability. Eur Psychiatry 2001,16(S1)(Suppl. 1),5s-24s","journal-title":"Eur Psychiatry"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1017\/S1041610213000094","volume":"25","author":"Nakatsuka M.","year":"2013","unstructured":"Nakatsuka M.; Meguro K.; Tsuboi H.; Nakamura K.; Akanuma K.; Yamaguchi S.; Content of delusional thoughts in Alzheimer\u2019s disease and assessment of content-specific brain dysfunctions with BEHAVE-AD-FW and SPECT. Int Psychogeriatr 2013,25(6),939-948","journal-title":"Int Psychogeriatr"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"Cummings J.L.","year":"1994","unstructured":"Cummings J.L.; Mega M.; Gray K.; Rosenberg-Thompson S.; Carusi D.A.; Gornbein J.; The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994,44(12),2308-2314","journal-title":"Neurology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1136\/jnnp.69.2.167","volume":"69","author":"Mega M.S.","year":"2000","unstructured":"Mega M.S.; Lee L.; Dinov I.D.; Mishkin F.; Toga A.W.; Cummings J.L.; Cerebral correlates of psychotic symptoms in Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 2000,69(2),167-171","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jns.2007.04.017","volume":"260","author":"Shinno H.","year":"2007","unstructured":"Shinno H.; Inagaki T.; Miyaoka T.; A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer\u2019s disease. J Neurol Sci 2007,260(1-2),132-138","journal-title":"J Neurol Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.schres.2014.11.010","volume":"161","author":"de Chazeron I.","year":"2015","unstructured":"de Chazeron I.; Pereira B.; Chereau-Boudet I.; Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and Parkinson\u2019s disease. Schizophr Res 2015,161(2-3),269-276","journal-title":"Schizophr Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"38152","DOI":"10.1038\/srep38152","volume":"6","author":"Llorca P.M.","year":"2016","unstructured":"Llorca P.M.; Pereira B.; Jardri R.; Hallucinations in schizophrenia and Parkinson\u2019s disease: An analysis of sensory modalities involved and the repercussion on patients. Sci Rep 2016,6(1),38152","journal-title":"Sci Rep"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.neubiorev.2017.02.021","volume":"83","author":"El Haj M.","year":"2017","unstructured":"El Haj M.; Roche J.; Jardri R.; Kapogiannis D.; Gallouj K.; Antoine P.; Clinical and neurocognitive aspects of hallucinations in Alzheimer\u2019s disease. Neurosci Biobehav Rev 2017,83,713-720","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1176\/ajp.146.8.1017","volume":"146","author":"Rubin E.H.","year":"1989","unstructured":"Rubin E.H.; Kinscherf D.A.; Psychopathology of very mild dementia of the Alzheimer type. Am J Psychiatry 1989,146(8),1017-1021","journal-title":"Am J Psychiatry"},{"key":"ref=52","first-page":"287","volume":"4","author":"Mangone C.A.","year":"1993","unstructured":"Mangone C.A.; Sanguinetti R.M.; Baumann P.D.; Influence of feelings of burden on the caregiver\u2019s perception of the patient\u2019s functional status. Dementia 1993,4(5),287-293","journal-title":"Dementia"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1176\/jnp.9.4.556","volume":"9","author":"Lyketsos C.G.","year":"1997","unstructured":"Lyketsos C.G.; Steele C.; Baker L.; Major and minor depression in Alzheimer\u2019s disease: Prevalence and impact. J Neuropsychiatry Clin Neurosci 1997,9(4),556-561","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/(SICI)1099-1166(200002)15:2<181::AID-GPS96>3.0.CO;2-I","volume":"15","author":"Gonz\u00e1lez-Salvador T.","year":"2000","unstructured":"Gonz\u00e1lez-Salvador T.; Lyketsos C.G.; Baker A.; Quality of life in dementia patients in long-term care. Int J Geriatr Psychiatry 2000,15(2),181-189","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=55","first-page":"8","volume":"15","author":"Alberca R.","year":"2000","unstructured":"Alberca R.; Gil-N\u00e9ciga E.; Salas D.; P\u00e9rez J.A.; Lozano P.; [Psychotic symptoms and Alzheimer\u2019s disease]. Neurologia 2000,15(1),8-14","journal-title":"Neurologia"},{"key":"ref=56","first-page":"108","volume":"5","author":"Rubin E.H.","year":"1992","unstructured":"Rubin E.H.; Delusions as part of alzheimer\u2019s disease. Neuropsychiatry Neuropsychol Behav Neurol 1992,5(2),108-113","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1212\/WNL.44.11.2055","volume":"44","author":"Starkstein S.E.","year":"1994","unstructured":"Starkstein S.E.; V\u00e1zquez S.; Petracca G.; A SPECT study of delusions in Alzheimer\u2019s disease. Neurology 1994,44(11),2055-2059","journal-title":"Neurology"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000084552","volume":"19","author":"Piccininni M.","year":"2005","unstructured":"Piccininni M.; Di Carlo A.; Baldereschi M.; Zaccara G.; Inzitari D.; Behavioral and psychological symptoms in Alzheimer\u2019s disease: Frequency and relationship with duration and severity of the disease. Dement Geriatr Cogn Disord 2005,19(5-6),276-281","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/archneur.55.4.539","volume":"55","author":"Binetti G.","year":"1998","unstructured":"Binetti G.; Mega M.S.; Magni E.; Behavioral disorders in Alzheimer disease: A transcultural perspective. Arch Neurol 1998,55(4),539-544","journal-title":"Arch Neurol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1212\/WNL.46.1.130","volume":"46","author":"Mega M.S.","year":"1996","unstructured":"Mega M.S.; Cummings J.L.; Fiorello T.; Gornbein J.; The spectrum of behavioral changes in Alzheimer\u2019s disease. Neurology 1996,46(1),130-135","journal-title":"Neurology"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/psyg.12108","volume":"15","author":"Tanaka H.","year":"2015","unstructured":"Tanaka H.; Hashimoto M.; Fukuhara R.; Relationship between dementia severity and behavioural and psychological symptoms in early-onset Alzheimer\u2019s disease. Psychogeriatrics 2015,15(4),242-247","journal-title":"Psychogeriatrics"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1176\/jnp.15.3.346","volume":"15","author":"Lopez O.L.","year":"2003","unstructured":"Lopez O.L.; Becker J.T.; Sweet R.A.; Psychiatric symptoms vary with the severity of dementia in probable Alzheimer\u2019s disease. J Neuropsychiatry Clin Neurosci 2003,15(3),346-353","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00415-013-6893-3","volume":"260","author":"Canevelli M.","year":"2013","unstructured":"Canevelli M.; Adali N.; Cantet C.; Impact of behavioral subsyndromes on cognitive decline in Alzheimer\u2019s disease: Data from the ICTUS study. J Neurol 2013,260(7),1859-1865","journal-title":"J Neurol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1532-5415.1990.tb05701.x","volume":"38","author":"Cooper J.K.","year":"1990","unstructured":"Cooper J.K.; Mungas D.; Weiler P.G.; Relation of cognitive status and abnormal behaviors in Alzheimer\u2019s disease. J Am Geriatr Soc 1990,38(8),867-870","journal-title":"J Am Geriatr Soc"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/00019442-200005000-00007","volume":"8","author":"Chen J.C.","year":"2000","unstructured":"Chen J.C.; Borson S.; Scanlan J.M.; Stage-specific prevalence of behavioral symptoms in Alzheimer\u2019s disease in a multi-ethnic community sample. Am J Geriatr Psychiatry 2000,8(2),123-133","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1001\/archneur.1987.00520160031010","volume":"44","author":"Cummings J.L.","year":"1987","unstructured":"Cummings J.L.; Miller B.; Hill M.A.; Neshkes R.; Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer type. Arch Neurol 1987,44(4),389-393","journal-title":"Arch Neurol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-0404.1993.tb04177.x","volume":"88","author":"Binetti G.","year":"1993","unstructured":"Binetti G.; Bianchetti A.; Padovani A.; Lenzi G.; De Leo D.; Trabucchi M.; Delusions in Alzheimer\u2019s disease and multi-infarct dementia. Acta Neurol Scand 1993,88(1),5-9","journal-title":"Acta Neurol Scand"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.58.6.907","volume":"58","author":"Sweet R.A.","year":"2002","unstructured":"Sweet R.A.; Nimgaonkar V.L.; Devlin B.; Lopez O.L.; DeKosky S.T.; Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology 2002,58(6),907-911","journal-title":"Neurology"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1192\/bjp.176.2.156","volume":"176","author":"Tunstall N.","year":"2000","unstructured":"Tunstall N.; Owen M.J.; Williams J.; Familial influence on variation in age of onset and behavioural phenotype in Alzheimer\u2019s disease. Br J Psychiatry 2000,176(2),156-159","journal-title":"Br J Psychiatry"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/brain\/awq001","volume":"133","author":"Sweet R.A.","year":"2010","unstructured":"Sweet R.A.; Bennett D.A.; Graff-Radford N.R.; Mayeux R.; Assessment and familial aggregation of psychosis in Alzheimer\u2019s disease from the National Institute on Aging Late Onset Alzheimer\u2019s Disease Family Study. Brain 2010,133(Pt 4),1155-1162","journal-title":"Brain"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"3116.e9","DOI":"10.1016\/j.neurobiolaging.2015.08.006","volume":"36","author":"Barral S.","year":"2015","unstructured":"Barral S.; Vardarajan B.N.; Reyes-Dumeyer D.; Genetic variants associated with susceptibility to psychosis in late-onset Alzheimer\u2019s disease families. Neurobiol Aging 2015,36(11),3116.e9-3116.e16","journal-title":"Neurobiol Aging"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/00019442-200507000-00011","volume":"13","author":"Bacanu S-A.","year":"2005","unstructured":"Bacanu S-A.; Devlin B.; Chowdari K.V.; DeKosky S.T.; Nimgaonkar V.L.; Sweet R.A.; Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry 2005,13(7),624-627","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/ajmg.b.30515","volume":"144B","author":"Hollingworth P.","year":"2007","unstructured":"Hollingworth P.; Hamshere M.L.; Holmans P.A.; Increased familial risk and genomewide significant linkage for Alzheimer\u2019s disease with psychosis. Am J Med Genet B Neuropsychiatr Genet 2007,144B(7),841-848","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3233\/JAD-2010-1274","volume":"19","author":"DeMichele-Sweet M.A.","year":"2010","unstructured":"DeMichele-Sweet M.A.; Sweet R.A.; Genetics of psychosis in Alzheimer\u2019s disease: A review. J Alzheimers Dis 2010,19(3),761-780","journal-title":"J Alzheimers Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1744-9081-8-62","volume":"8","author":"Christie D.","year":"2012","unstructured":"Christie D.; Shofer J.; Millard S.P.; Genetic association between APOE*4 and neuropsychiatric symptoms in patients with probable Alzheimer\u2019s disease is dependent on the psychosis phenotype. Behav Brain Funct 2012,8(1),62","journal-title":"Behav Brain Funct"},{"key":"ref=76","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/926597","volume":"2011","author":"Demichele-Sweet M.A.A.","year":"2011","unstructured":"Demichele-Sweet M.A.A.; Lopez O.L.; Sweet R.A.; Psychosis in Alzheimer\u2019s disease in the national Alzheimer\u2019s disease coordinating center uniform data set: Clinical correlates and association with apolipoprotein e. Int J Alzheimers Dis 2011,2011","journal-title":"Int J Alzheimers Dis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2328.e1","DOI":"10.1016\/j.neurobiolaging.2011.06.016","volume":"32","author":"Chu S.H.","year":"2011","unstructured":"Chu S.H.; Roeder K.; Ferrell R.E.; TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease. Neurobiol Aging 2011,32(12),2328.e1-2328.e9","journal-title":"Neurobiol Aging"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/hmg\/7.9.1507","volume":"7","author":"Holmes C.","year":"1998","unstructured":"Holmes C.; Arranz M.J.; Powell J.F.; Collier D.A.; Lovestone S.; 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer\u2019s disease. Hum Mol Genet 1998,7(9),1507-1509","journal-title":"Hum Mol Genet"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.neurobiolaging.2006.10.011","volume":"29","author":"Pritchard A.L.","year":"2008","unstructured":"Pritchard A.L.; Harris J.; Pritchard C.W.; Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer\u2019s disease. Neurobiol Aging 2008,29(3),341-347","journal-title":"Neurobiol Aging"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/archneur.61.8.1249","volume":"61","author":"Assal F.","year":"2004","unstructured":"Assal F.; Alarc\u00f3n M.; Solomon E.C.; Masterman D.; Geschwind D.H.; Cummings J.L.; Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol 2004,61(8),1249-1253","journal-title":"Arch Neurol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/gps.1109","volume":"19","author":"Lam L.C.W.","year":"2004","unstructured":"Lam L.C.W.; Tang N.L.S.; Ma S.L.; Zhang W.; Chiu H.F.K.; 5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer\u2019s disease. Int J Geriatr Psychiatry 2004,19(6),523-526","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/mp.2017.81","volume":"23","author":"DeMichele-Sweet M.A.A.","year":"2018","unstructured":"DeMichele-Sweet M.A.A.; Weamer E.A.; Klei L.; Genetic risk for schizophrenia and psychosis in Alzheimer disease. Mol Psychiatry 2018,23(4),963-972","journal-title":"Mol Psychiatry"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1038\/s41380-021-01152-8","volume":"26","author":"DeMichele-Sweet M.A.A.","year":"2021","unstructured":"DeMichele-Sweet M.A.A.; Klei L.; Creese B.; Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Mol Psychiatry 2021,26(10),5797-5811","journal-title":"Mol Psychiatry"},{"key":"ref=84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111462","volume":"9","author":"Zheng X.","year":"2014","unstructured":"Zheng X.; Demirci F.Y.; Barmada M.M.; A rare duplication on chromosome 16p11.2 is identified in patients with psychosis in Alzheimer\u2019s disease. PLoS One 2014,9(11)","journal-title":"PLoS One"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1038\/tp.2015.64","volume":"5","author":"Zheng X.","year":"2015","unstructured":"Zheng X.; Demirci F.Y.; Barmada M.M.; Genome-wide copy-number variation study of psychosis in Alzheimer\u2019s disease. Transl Psychiatry 2015,5(6),e574-e4","journal-title":"Transl Psychiatry"},{"key":"ref=86","doi-asserted-by":"publisher","DOI":"10.1101\/528802","author":"Creese B.","year":"2019","unstructured":"Creese B.; Vassos E.; Bergh S.; Athanasiu L.; Johar I.; Rongve A.; Association between schizophrenia polygenic score and psychotic symptoms in Alzheimer\u2019s disease: Meta-analysis of 11 cohort studies. BioRxiv 2019","journal-title":"BioRxiv"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.neurobiolaging.2020.01.001","volume":"89","author":"Pishva E.","year":"2020","unstructured":"Pishva E.; Creese B.; Smith A.R.; Psychosis-associated DNA methylomic variation in Alzheimer\u2019s disease cortex. Neurobiol Aging 2020,89,83-88","journal-title":"Neurobiol Aging"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/brain\/awn151","volume":"131","author":"Bruen P.D.","year":"2008","unstructured":"Bruen P.D.; McGeown W.J.; Shanks M.F.; Venneri A.; Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer\u2019s disease. Brain 2008,131(Pt 9),2455-2463","journal-title":"Brain"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/archpsyc.57.12.1165","volume":"57","author":"Farber N.B.","year":"2000","unstructured":"Farber N.B.; Rubin E.H.; Newcomer J.W.; Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry 2000,57(12),1165-1173","journal-title":"Arch Gen Psychiatry"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"906 LP","DOI":"10.1212\/WNL.41.6.906","volume":"41","author":"Lopez O.L.","year":"1991","unstructured":"Lopez O.L.; Becker J.T.; Brenner R.P.; Rosen J.; Bajulaiye O.I.; Reynolds C.F.; Alzheimer\u2019s disease with delusions and hallucinations. Neurology 1991,41(6),906 LP","journal-title":"Neurology"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1176\/appi.ajp.157.5.708","volume":"157","author":"Lyketsos C.G.","year":"2000","unstructured":"Lyketsos C.G.; Steinberg M.; Tschanz J.T.; Norton M.C.; Steffens D.C.; Breitner J.C.S.; Mental and behavioral disturbances in dementia: Findings from the cache county study on memory in aging. Am J Psychiatry 2000,157(5),708-714","journal-title":"Am J Psychiatry"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1176\/jnp.2006.18.2.191","volume":"18","author":"Lee D.Y.","year":"2006","unstructured":"Lee D.Y.; Choo I.H.; Kim K.W.; White matter changes associated with psychotic symptoms in Alzheimer\u2019s disease patients. J Neuropsychiatry Clin Neurosci 2006,18(2),191-198","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/brain\/118.1.279","volume":"118","author":"Devinsky O.","year":"1995","unstructured":"Devinsky O.; Morrell M.J.; Vogt B.A.; Contributions of anterior cingulate cortex to behaviour. Brain 1995,118(Pt 1),279-306","journal-title":"Brain"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/ene.13076","volume":"23","author":"Boublay N.","year":"2016","unstructured":"Boublay N.; Schott A.M.; Krolak-Salmon P.; Neuroimaging correlates of neuropsychiatric symptoms in Alzheimer\u2019s disease: A review of 20 years of research. Eur J Neurol 2016,23(10),1500-1509","journal-title":"Eur J Neurol"},{"key":"ref=95","first-page":"89","volume":"202","year":"2012","unstructured":"Neuroimaging of delusions in Alzheimer\u2019s disease. Mulsantab Z-QEFAS H.2012,202(2),89-95"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archpsyc.1989.01810030049007","volume":"46","author":"Baxter L.R.","year":"1989","unstructured":"Baxter L.R.; Schwartz J.M.; Phelps M.E.; Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989,46(3),243-250","journal-title":"Arch Gen Psychiatry"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1176\/ajp.152.10.1470","volume":"152","author":"Kotrla K.J.","year":"1995","unstructured":"Kotrla K.J.; Chacko R.C.; Harper R.G.; Jhingran S.; Doody R.; SPECT findings on psychosis in Alzheimer\u2019s disease. Am J Psychiatry 1995,152(10),1470-1475","journal-title":"Am J Psychiatry"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1176\/jnp.13.1.50","volume":"13","author":"Lopez O.L.","year":"2001","unstructured":"Lopez O.L.; Smith G.; Becker J.T.; Meltzer C.C.; DeKosky S.T.; The psychotic phenomenon in probable Alzheimer\u2019s disease: A positron emission tomography study. J Neuropsychiatry Clin Neurosci 2001,13(1),50-55","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=99","first-page":"211","author":"Ismail Z","year":"2011","unstructured":"Ismail Z; Nguyen M; Mulsant BH; Mamo D;  Neurobiology of delusions in alzheimer \u2019 s disease 2011,211-218","journal-title":"Neurobiology of delusions in alzheimer \u2019 s disease"},{"key":"ref=100","author":"George S","year":"1991","unstructured":"George S; Moossy John; Martinez M Julio; Neuropathologic and neurochemical correlates of psychosis in primary dementia. 1991"},{"key":"ref=101","first-page":"57","author":"Mukaetova-Ladinska EB","year":"1995","unstructured":"Mukaetova-Ladinska EB; Harrington CR; Xuereb J; Roth M; Wischik CM; Biochemical, neuropathological, and clinical correlations of neurofibrillary degeneration in Alzheimer\u2019s disease. Biochem Neuropathol Clin Correl neurofibrillary degenration Alzheimer\u2019s Dis Springer Publ New York 1995,57-80","journal-title":"Biochem Neuropathol Clin Correl neurofibrillary degenration Alzheimer\u2019s Dis Springer Publ New York"},{"key":"ref=102","volume":"57","author":"Lai MK P","year":"2001","unstructured":"Lai MK P; Lai O \u2013F; Keene J; Esiri MM; Francis PT; Hope T; Psychosis of Alzheimer\u2019s disease is associated with elevated muscarinic M2 binding in the cortex. Neurology 2001,57(5)","journal-title":"Neurology"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/01.wnl.0000341932.21961.f3","volume":"72","author":"Reeves S.","year":"2009","unstructured":"Reeves S.; Brown R.; Howard R.; Grasby P.; Increased striatal dopamine (D2\/D3) receptor availability and delusions in Alzheimer disease. Neurology 2009,72(6),528-534","journal-title":"Neurology"},{"key":"ref=104","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6798712","volume":"2018","author":"Olivero P.","year":"2018","unstructured":"Olivero P.; Lozano C.; Sotomayor-Z\u00e1rate R.; Proteostasis and mitochondrial role on psychiatric and neurodegenerative disorders: Current perspectives. Neural Plast 2018,2018","journal-title":"Neural Plast"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"11461","DOI":"10.1007\/s11356-020-07914-1","volume":"27","author":"Elmatboly A.M.","year":"2020","unstructured":"Elmatboly A.M.; Sherif A.M.; Deeb D.A.; The impact of proteostasis dysfunction secondary to environmental and genetic causes on neurodegenerative diseases progression and potential therapeutic intervention. Environ Sci Pollut Res Int 2020,27(11),11461-11483","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3233\/JAD-131166","volume":"39","author":"Murray P.S.","year":"2014","unstructured":"Murray P.S.; Kirkwood C.M.; Gray M.C.; Hyperphosphorylated tau is elevated in Alzheimer\u2019s disease with psychosis. J Alzheimers Dis 2014,39(4),759-773","journal-title":"J Alzheimers Dis"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"20858","DOI":"10.1038\/srep20858","volume":"6","author":"Ting S.K.S.","year":"2016","unstructured":"Ting S.K.S.; Hao Y.; Chia P.S.; Tan E-K.; Hameed S.; Clinicopathological correlation of psychosis and brain vascular changes in Alzheimer\u2019s disease. Sci Rep 2016,6(1),20858","journal-title":"Sci Rep"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/YCO.0000000000000476","volume":"32","author":"Karameh W.K.","year":"2019","unstructured":"Karameh W.K.; Murari G.; Schweizer T.A.; Munoz D.G.; Fischer C.E.; Psychosis in neurodegenerative disorders: Recent developments. Curr Opin Psychiatry 2019,32(2),117-122","journal-title":"Curr Opin Psychiatry"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1176\/appi.ajp.2018.17080858","volume":"175","author":"Krivinko J.M.","year":"2018","unstructured":"Krivinko J.M.; Erickson S.L.; Ding Y.; Synaptic proteome compensation and resilience to psychosis in Alzheimer\u2019s disease. Am J Psychiatry 2018,175(10),999-1009","journal-title":"Am J Psychiatry"},{"key":"ref=110","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.07.21262904","author":"DeChellis-Marks M.R.","year":"2021","unstructured":"DeChellis-Marks M.R.; Wei Y.; Ding Y.; Wolfe C.M.; Krivinko J.M.; MacDonald M.L.; Psychosis in Alzheimer\u2019s disease is associated with excitatory neuron vulnerability and post-transcriptional mechanisms altering synaptic protein levels. medRxiv 2021","journal-title":"medRxiv"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3390\/molecules22101692","volume":"22","author":"Penke B","year":"2017","unstructured":"Penke B; Bog\u00e1r F; F\u00fcl\u00f6p L.; \u03b2-Amyloid and the pathomechanisms of Alzheimer\u2019s disease: A comprehensive view. Molecules 2017,22(10),1692","journal-title":"Molecules"},{"key":"ref=112","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/260925","volume":"2013","author":"Fuster-Matanzo A.","year":"2013","unstructured":"Fuster-Matanzo A.; Llorens-Mart\u00edn M.; Hern\u00e1ndez F.; Avila J.; Role of neuroinflammation in adult neurogenesis and Alzheimer disease: Therapeutic approaches. Mediators Inflamm 2013,2013","journal-title":"Mediators Inflamm"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.exger.2017.10.024","volume":"105","author":"Pawelec G.","year":"2018","unstructured":"Pawelec G.; Age and immunity: What is \u201cimmunosenescence\u201d? Exp Gerontol 2018,105,4-9","journal-title":"Exp Gerontol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"8071","DOI":"10.1007\/s12035-016-0297-1","volume":"54","author":"Sochocka M.","year":"2017","unstructured":"Sochocka M.; Diniz B.S.; Leszek J.; Inflammatory response in the CNS: Friend or foe? Mol Neurobiol 2017,54(10),8071-8089","journal-title":"Mol Neurobiol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.exger.2017.12.019","volume":"107","author":"Le Page A.","year":"2018","unstructured":"Le Page A.; Dupuis G.; Frost E.H.; Role of the peripheral innate immune system in the development of Alzheimer\u2019s disease. Exp Gerontol 2018,107,59-66","journal-title":"Exp Gerontol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1742-2094-2-9","volume":"2","author":"Patel N.S.","year":"2005","unstructured":"Patel N.S.; Paris D.; Mathura V.; Quadros A.N.; Crawford F.C.; Mullan M.J.; Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer\u2019s disease. J Neuroinflammation 2005,2(1),9","journal-title":"J Neuroinflammation"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/jnnp.74.9.1200","volume":"74","author":"Tarkowski E.","year":"2003","unstructured":"Tarkowski E.; Andreasen N.; Tarkowski A.; Blennow K.; Intrathecal inflammation precedes development of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 2003,74(9),1200-1205","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.brainresbull.2014.09.003","volume":"108","author":"Holmgren S.","year":"2014","unstructured":"Holmgren S.; Hjorth E.; Schultzberg M.; Neuropsychiatric symptoms in dementia-a role for neuroinflammation? Brain Res Bull 2014,108,88-93","journal-title":"Brain Res Bull"},{"key":"ref=119","author":"Haroon E","year":"2012","unstructured":"Haroon E; Raison CL; Miller AH; Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. 2012"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bbi.2012.06.010","volume":"31","author":"Di Nicola M.","year":"2013","unstructured":"Di Nicola M.; Cattaneo A.; Hepgul N.; Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun 2013,31,90-95","journal-title":"Brain Behav Immun"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.biopsych.2008.10.018","volume":"65","author":"Song X-Q.","year":"2009","unstructured":"Song X-Q.; Lv L-X.; Li W-Q.; Hao Y-H.; Zhao J-P.; The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 2009,65(6),481-488","journal-title":"Biol Psychiatry"},{"key":"ref=122","first-page":"S153","volume":"24","author":"Kubistova A.","year":"2012","unstructured":"Kubistova A.; Horacek J.; Novak T.; Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr Danub 2012,24(Suppl. 1),S153-S156","journal-title":"Psychiatr Danub"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1192\/bjp.bp.108.052605","volume":"194","author":"Fernandez-Egea E.","year":"2009","unstructured":"Fernandez-Egea E.; Bernardo M.; Donner T.; Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 2009,194(5),434-438","journal-title":"Br J Psychiatry"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0920-9964(00)00007-4","volume":"47","author":"Theodoropoulou S.","year":"2001","unstructured":"Theodoropoulou S.; Spanakos G.; Baxevanis C.N.; Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 2001,47(1),13-25","journal-title":"Schizophr Res"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s12035-018-1188-4","volume":"56","author":"Sochocka M.","year":"2019","unstructured":"Sochocka M.; Donskow-\u0141ysoniewska K.; Diniz BS.; Kurpas D.; Brzozowska E.; Leszek J.; The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer\u2019s disease\u2014a critical review. Mol Neurobiol 2019,56(3),1841-1851","journal-title":"Mol Neurobiol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.3748\/wjg.v23.i30.5486","volume":"23","author":"Cenit M.C.","year":"2017","unstructured":"Cenit M.C.; Sanz Y.; Codo\u00f1er-Franch P.; Influence of gut microbiota on neuropsychiatric disorders. World J Gastroenterol 2017,23(30),5486-5498","journal-title":"World J Gastroenterol"},{"key":"ref=127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060726","volume":"8","author":"Nagele E.P.","year":"2013","unstructured":"Nagele E.P.; Han M.; Acharya N.K.; DeMarshall C.; Kosciuk M.C.; Nagele R.G.; Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One 2013,8(4)","journal-title":"PLoS One"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00011-007-6213-4","volume":"57","author":"Mihaylova N.M.","year":"2008","unstructured":"Mihaylova N.M.; Dimitrov J.D.; Djoumerska-Alexieva I.K.; Vassilev T.L.; Inflammation-induced enhancement of IgG immunoreactivity. Inflamm Res 2008,57(1),1-3","journal-title":"Inflamm Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.4049\/jimmunol.176.4.2095","volume":"176","author":"Denny M.F.","year":"2006","unstructured":"Denny M.F.; Chandaroy P.; Killen P.D.; Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol 2006,176(4),2095-2104","journal-title":"J Immunol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaut.2007.07.007","volume":"29","author":"Lutz H.U.","year":"2007","unstructured":"Lutz H.U.; Homeostatic roles of naturally occurring antibodies: An overview. J Autoimmun 2007,29(4),287-294","journal-title":"J Autoimmun"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3389\/fimmu.2017.00752","volume":"8","author":"Zong S.","year":"2017","unstructured":"Zong S.; Hoffmann C.; Man\u00e9-Damas M.; Molenaar P.; Losen M.; Martinez-Martinez P.; Neuronal surface autoantibodies in neuropsychiatric disorders: Are there implications for depression? Front Immunol 2017,8,752","journal-title":"Front Immunol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neubiorev.2014.01.008","volume":"40","author":"Iseme R.A.","year":"2014","unstructured":"Iseme R.A.; McEvoy M.; Kelly B.; Agnew L.; Attia J.; Walker F.R.; Autoantibodies and depression: Evidence for a causal link? Neurosci Biobehav Rev 2014,40,62-79","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1191\/0961203303lu409oa","volume":"12","author":"Shoenfeld Y.","year":"2003","unstructured":"Shoenfeld Y.; Nahum A.; Korczyn A.D.; Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003,12(6),436-442","journal-title":"Lupus"},{"key":"ref=134","doi-asserted-by":"publisher","DOI":"10.2217\/1745509X.4.1.47","author":"Bowman GL","year":"2008","unstructured":"Bowman GL; Quinn JF; Alzheimer\u2019s disease and the blood\u2013brain barrier: Past, present and future. 2008"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1084\/jem.20031763","volume":"200","author":"Chang M-K.","year":"2004","unstructured":"Chang M-K.; Binder C.J.; Miller Y.I.; Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 2004,200(11),1359-1370","journal-title":"J Exp Med"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nm.3913","volume":"21","author":"Zenaro E.","year":"2015","unstructured":"Zenaro E.; Pietronigro E.; Della Bianca V.; Neutrophils promote Alzheimer\u2019s disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med 2015,21(8),880-886","journal-title":"Nat Med"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.exger.2015.03.002","volume":"65","author":"Hohsfield L.A.","year":"2015","unstructured":"Hohsfield L.A.; Humpel C.; Migration of blood cells to \u03b2-amyloid plaques in Alzheimer\u2019s disease. Exp Gerontol 2015,65,8-15","journal-title":"Exp Gerontol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40478-015-0187-1","volume":"3","author":"Arendt T.","year":"2015","unstructured":"Arendt T.; Br\u00fcckner M.K.; Morawski M.; J\u00e4ger C.; Gertz H-J.; Early neurone loss in Alzheimer\u2019s disease: Cortical or subcortical? Acta Neuropathol Commun 2015,3(1),10","journal-title":"Acta Neuropathol Commun"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00109-018-1709-7","volume":"96","author":"Waisman A.","year":"2018","unstructured":"Waisman A.; Johann L.; Antigen-presenting cell diversity for T cell reactivation in central nervous system autoimmunity. J Mol Med (Berl) 2018,96(12),1279-1292","journal-title":"J Mol Med (Berl)"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7555\/JBR.30.20150131","volume":"30","author":"Wu J.","year":"2016","unstructured":"Wu J.; Li L.; Autoantibodies in Alzheimer\u2019s disease: Potential biomarkers, pathogenic roles, and therapeutic implications. J Biomed Res 2016,30(5),361-372","journal-title":"J Biomed Res"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JAD-150053","volume":"47","author":"Giil L.M.","year":"2015","unstructured":"Giil L.M.; Kristoffersen E.K.; Vedeler C.A.; Autoantibodies toward the angiotensin 2 type 1 receptor: A novel autoantibody in Alzheimer\u2019s disease. J Alzheimers Dis 2015,47(2),523-529","journal-title":"J Alzheimers Dis"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-3083.2012.02684.x","volume":"75","author":"Karczewski P.","year":"2012","unstructured":"Karczewski P.; Hempel P.; Kunze R.; Bimmler M.; Agonistic autoantibodies to the \u03b1(1) -adrenergic receptor and the \u03b2(2) -adrenergic receptor in Alzheimer\u2019s and vascular dementia. Scand J Immunol 2012,75(5),524-530","journal-title":"Scand J Immunol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neures.2014.06.002","volume":"85","author":"Busse S.","year":"2014","unstructured":"Busse S.; Brix B.; Kunschmann R.; Bogerts B.; Stoecker W.; Busse M.; N-methyl-d-aspartate glutamate receptor (NMDA-R) antibodies in mild cognitive impairment and dementias. Neurosci Res 2014,85,58-64","journal-title":"Neurosci Res"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1177\/002215540205000603","volume":"50","author":"Witmer A.N.","year":"2002","unstructured":"Witmer A.N.; Dai J.; Weich H.A.; Vrensen G.F.J.M.; Schlingemann R.O.; Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem 2002,50(6),767-777","journal-title":"J Histochem Cytochem"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3233\/JAD-170245","volume":"59","author":"Giil L.M.","year":"2017","unstructured":"Giil L.M.; Vedeler C.A.; Kristoffersen E.K.; Antibodies to signaling molecules and receptors in Alzheimer\u2019s disease are associated with psychomotor slowing, depression, and poor visuospatial function. J Alzheimers Dis 2017,59(3),929-939","journal-title":"J Alzheimers Dis"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3233\/JAD-170882","volume":"64","author":"Giil L.M.","year":"2018","unstructured":"Giil L.M.; Aarsland D.; Hellton K.; Antibodies to multiple receptors are associated with neuropsychiatric symptoms and mortality in Alzheimer\u2019s disease: A longitudinal study. J Alzheimers Dis 2018,64(3),761-774","journal-title":"J Alzheimers Dis"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/appi.neuropsych.20060152","volume":"33","author":"Cummings J.","year":"2021","unstructured":"Cummings J.; Drug development for psychotropic, cognitive-enhancing, and disease-modifying treatments for Alzheimer\u2019s disease. J Neuropsychiatry Clin Neurosci 2021,33(1),3-13","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1474-4422(18)30052-8","volume":"17","author":"Schneider L.S.","year":"2018","unstructured":"Schneider L.S.; Pimavanserin for patients with Alzheimer\u2019s disease psychosis. Lancet Neurol 2018,17(3),194-195","journal-title":"Lancet Neurol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","volume":"17","author":"Ballard C.","year":"2018","unstructured":"Ballard C.; Banister C.; Khan Z.; Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: A phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol 2018,17(3),213-222","journal-title":"Lancet Neurol"},{"key":"ref=150","volume":"6","author":"Ballard C","year":"2019","unstructured":"Ballard C; Youakim JM; Coate SS B; Pimavanserin in alzheimer\u2019s disease psychosis: Efficacy in patients with more pronounced psychotic symptoms. J Prev Alzheimer\u2019s Dis - JPAD\u00a9 2019,6(1)","journal-title":"J Prev Alzheimer\u2019s Dis - JPAD\u00a9"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa2034634","volume":"385","author":"Tariot P.N.","year":"2021","unstructured":"Tariot P.N.; Cummings J.L.; Soto-Martin M.E.; Trial of Pimavanserin in Dementia-Related Psychosis. N Engl J Med 2021,385(4),309-319","journal-title":"N Engl J Med"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","volume":"57","author":"Street J.S.","year":"2000","unstructured":"Street J.S.; Clark W.S.; Gannon K.S.; Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000,57(10),968-976","journal-title":"Arch Gen Psychiatry"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/CIA.S4250","volume":"3","author":"Campbell N.","year":"2008","unstructured":"Campbell N.; Ayub A.; Boustani M.A.; Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer\u2019s disease: A meta-analysis. Clin Interv Aging 2008,3(4),719-728","journal-title":"Clin Interv Aging"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cns.12484","volume":"22","author":"Cummings J.","year":"2016","unstructured":"Cummings J.; Lai T.J.; Hemrungrojn S.; Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer\u2019s disease and dementia with lewy bodies. CNS Neurosci Ther 2016,22(3),159-166","journal-title":"CNS Neurosci Ther"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"Porsteinsson A.P.","year":"2014","unstructured":"Porsteinsson A.P.; Drye L.T.; Pollock B.G.; Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA 2014,311(7),682-691","journal-title":"JAMA"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jagp.2021.04.014","volume":"30","author":"Devanand DP","year":"2022","unstructured":"Devanand DP; Crocco E; Forester BP; Husain MM; Lee S; Vahia I V; Low Dose lithium treatment of behavioral complications in alzheimer\u2019s disease: lit-ad randomized clinical trial. Am J Geriatr psychiatry Off J Am Assoc Geriatr Psychiatry 2022,30(1),32-34","journal-title":"Am J Geriatr psychiatry Off J Am Assoc Geriatr Psychiatry"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3233\/JAD-150943","volume":"53","author":"Landel V.","year":"2016","unstructured":"Landel V.; Annweiler C.; Millet P.; Vitamin D, cognition and Alzheimer\u2019s disease: The therapeutic benefit is in the D-tails. J Alzheimers Dis 2016,53(2),419-444","journal-title":"J Alzheimers Dis"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jagp.2019.03.016","volume":"27","author":"Wang L.","year":"2019","unstructured":"Wang L.; Ying J.; Fan P.; Effects of vitamin D use on outcomes of psychotic symptoms in Alzheimer disease patients. Am J Geriatr Psychiatry 2019,27(9),908-917","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000486597","volume":"24","author":"Vakilian A.","year":"2017","unstructured":"Vakilian A.; Razavi-Nasab S.M.; Ravari A.; Vitamin B12 in association with antipsychotic drugs can modulate the expression of pro-\/anti-inflammatory cytokines in Alzheimer disease patients. Neuroimmunomodulation 2017,24(6),310-319","journal-title":"Neuroimmunomodulation"},{"key":"ref=160","volume":"2015","author":"De Oliveira AM","year":"2015","unstructured":"De Oliveira AM; Radanovic M; De Mello PCH; Buchain PC; Vizzotto ADB; Celestino DL; Non-pharmacological interventions to reduce behavioral and psychological symptoms of dementia: A systematic review. BioMed Res Int 2015,2015","journal-title":"BioMed Res Int"},{"key":"ref=161","first-page":"1","volume":"48","author":"Manuscript A.","year":"2010","unstructured":"Manuscript A.; Syndromes G.P.;  Five Things That Healthcare Providers and Patients Should Question 2010,48(Suppl. 2),1-6","journal-title":"Five Things That Healthcare Providers and Patients Should Question"},{"key":"ref=162","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h369","author":"Kales HC","year":"2015","unstructured":"Kales HC; Gitlin LN; Lyketsos CG; Assessment and management of behavioral and psychological symptoms of dementia. BMJ 350(mar02 7): h369.2015","journal-title":"BMJ"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1479-8301.2010.00329.x","volume":"11","author":"Moretti F.","year":"2011","unstructured":"Moretti F.; De Ronchi D.; Bernabei V.; Pet therapy in elderly patients with mental illness. Psychogeriatrics 2011,11(2),125-129","journal-title":"Psychogeriatrics"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1017\/S1041610218000534","volume":"31","author":"Kales H.C.","year":"2019","unstructured":"Kales H.C.; Lyketsos C.G.; Miller E.M.; Ballard C.; Management of behavioral and psychological symptoms in people with Alzheimer\u2019s disease: An international Delphi consensus. Int Psychogeriatr 2019,31(1),83-90","journal-title":"Int Psychogeriatr"}],"container-title":["Current Alzheimer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567205019666220418151914","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/203757\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567205019666220418151914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T21:28:52Z","timestamp":1691789332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/203757\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":164,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567205019666220418151914","relation":{},"ISSN":["1567-2050"],"issn-type":[{"value":"1567-2050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}